Study Overview: This study looks at how common a condition called hypercortisolism is in people with Type 2 Diabetes (T2D) that is hard to control. Hypercortisolism means having too much cortisol, a hormone, in the body. The study has two parts. Part 1 checks how many people with difficult-to-control T2D have hypercortisolism. Part 2 tests a medicine called mifepristone (Korlym®) to see if it helps patients with both hard-to-control T2D and hypercortisolism.

• Study Duration: Part 1 is non-interventional; Part 2 involves taking mifepristone or a placebo once daily.
• Eligibility: Must have difficult-to-control T2D; certain medical conditions and treatments may exclude participation.
• Risks and Benefits: In Part 2, the safety and effectiveness of mifepristone are tested; risks may include side effects.

Note: To participate, patients should not have type 1 diabetes, recent diabetes, or certain other conditions. Women who are pregnant or breastfeeding cannot join. If you have questions, talk to your doctor to see if this study is right for you.